Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials
Mattía Galli(Maria Cecilia Hospital), Dominick J. Angiolillo(University of Florida), Naveen L. Pereira(Mayo Clinic), Roxana Mehran(Mount Sinai Hospital), Francesco Franchi(Florida College), Fabiana Rollini(Florida College), Filippo Crea(Università Cattolica del Sacro Cuore), Behnood Bikdeli(Broad Institute), Larisa H. Cavallari(University of Florida), Giovanni Maria Vescovo(Ospedale dell' Angelo), Giuseppe Biondi‐Zoccai(Maria Cecilia Hospital), Dirk Sibbing(Ludwig-Maximilians-Universität München), Stefano Benenati(Ospedale Policlinico San Martino), C. Michael Gibson(Baim Institute for Clinical Research), Davide Capodanno(University of Catania), Jurriën M. ten Berg(St. Antonius Ziekenhuis)
Cited by 150
Related Papers
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
2024 ESC Guidelines for the management of chronic coronary syndromes
|European Heart Journal|2024|2.3k